Best in Biotech 22 Jan 2025 Curing ALS? Sixteen companies developing new treatments in 2025 …defenses for therapeutic purposes. This process involves sequencing immune B-cells to discover antibodies common among resilient individuals but absent in typical disease progressors. The goal is to develop therapies that… January 22, 2025 - 18 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 3 Nov 2022 What’s on the horizon for gene editing-based therapies? …Arbor Biotechnologies. He added that much of the interest in the technology is its potential to not just treat diseases, but to cure them. The most advanced CRISPR-based cell therapies… November 3, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine …the integrity of the vesicle membrane, freeing the drug to perform its role in the target cell. The mechanism by which PCI technology helps therapeutic drugs to enter target cells…. September 12, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2025 Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? …that may not have that rationale,” Masoud Tavazoie told Labiotech, a few years ago. “Over the next two to three years, we’re gonna start to see the real winners. And… January 17, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Startup Scout 22 Feb 2019 This Biotech’s Algorithm Accelerates Cell Therapy Development …them into the therapeutic cell that you want. This is not a simple process, and it can take significant amounts of time and money. The stem cell stage can be… February 22, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Dec 2017 Biotech and Pharma Giants Make a Good Start to Phase II Trial for Skin Cancer …mechanisms used by tumors to protect themselves from the immune system. In particular, PD-1 tells T cells not to attack cells that express its ligand, PD-L1. Checkpoint inhibitors that block… December 13, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instability …that cells that overcome CRISPR editing might do so precisely because of defective p53 functioning. That is to say, these cells may be less able to detect DNA damage and/or… August 9, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2023 10 biotech companies making a difference in rare diseases …part of a drug regimen to treat chronic granulomatous disease (CGD); Buphenyl, used to treat urea cycle disorders; Krystexxa, to treat gout; Procysbi, to treat nephropathic cystinosis; Ravicti, to manage… February 28, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2023 Faux filet: World’s first 3D-printed ready-to-cook fish produced …that are grown in laboratories, are obtained from the startup’s proprietary 3D bioprinters and customized bio-inks. Said to have the same taste and texture as traditionally caught fish, this invention… June 2, 2023 - 3 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2018 Two Biotechs Team Up to Test their Cancer Antibody Combo in the Clinic …a Phase I trial to select a dose that can be used at Phase II to test the combination’s safety and efficacy. Durvalumab is a checkpoint inhibitor that blocks PD-L1… January 30, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded …all rodent cells derived from these genetically modified rodent animals. It also includes the genetic manipulation of rodent embryonic stem cells and rodent embryos to create genetically modified rodent animals…. September 8, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2018 Roche Acquires UK Cancer Immunotherapy Biotech in Deal Worth up to €655M …cells called regulatory T cells. These cells hold back the immune system from attacking tumors, thus the antibody helps the patient’s immune system to fight the cancer. The antibody has… September 28, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email